GAVRETO® Manufacturedby Roche is a once-daily oral targeted therapy for people living with RET-positive (RET+) metastatic non–small cell lung cancer (NSCLC) or advanced thyroid cancer. GAVRETO is a prescription medicine used to treat certain cancers caused by abnormal rearranged during transfection (RET) gene in:
- adults with non-small cell lung cancer (NSCLC) that has spread
- adults and children 12 years of age and older with advanced medullary thyroid cancer (MTC) or MTC that has spread who require a medicine by mouth or injection (systemic therapy)
- adults and children 12 years of age and older with advanced thyroid cancer or thyroid cancer that has spread who require a medicine by mouth or injection (systemic therapy) and who have received radioactive iodine and it did not work or is no longer working
Your healthcare provider will perform a test to make sure that GAVRETO is right for you.
GAVRETO was approved based on the percentage of patients whose tumor size shrank or disappeared after treatment and how long that response lasted. There are ongoing studies to confirm the benefit of GAVRETO.